Ther Drug Monit 2017 Aug;39(4):333-338
Departments of *Hospital Pharmacy, †Dermatology, and ‡Immunology, Erasmus MC, Rotterdam, the Netherlands; §Department of R&D, Sanquin Reagents, Amsterdam, the Netherlands; ¶Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, the Netherlands; and ‖Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.
: Etanercept has shown to mediate a favorable effect on immune-mediated inflammatory diseases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept could improve clinical outcome and cost-effectiveness. A high intrapatient variability (IPV) of etanercept trough concentrations at standard dosing would reduce the feasibility of therapeutic drug monitoring. Read More